Difference between revisions of "Ovarian cancer screening"

Jump to: navigation, search
(4 intermediate revisions by the same user not shown)
Line 5: Line 5:
 
Please help WikiDoc by adding content here.  It's easy!  Click  [[Help:How to Edit a Page|here]]  to learn about editing.
 
Please help WikiDoc by adding content here.  It's easy!  Click  [[Help:How to Edit a Page|here]]  to learn about editing.
  
*There are no recommendations for screening ovarian cancer in asymptomatic women although better outcome is associated with early diagnosis<ref name="pmid27284942">{{cite journal| author=Galea M, Gauci G, Calleja-Agius J, Schembri-Wismayer P| title=Peritoneal biomarkers in the early detection of ovarian cancer. | journal=Minerva Ginecol | year= 2017 | volume= 69 | issue= 1 | pages= 84-99 | pmid=27284942 | doi=10.23736/S0026-4784.16.03943-5 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27284942  }} </ref>
+
*There are no recommendations for [[screening]] [[ovarian cancer]] in asymptomatic women although better outcome is associated with early [[diagnosis]]<ref name="pmid27284942">{{cite journal| author=Galea M, Gauci G, Calleja-Agius J, Schembri-Wismayer P| title=Peritoneal biomarkers in the early detection of ovarian cancer. | journal=Minerva Ginecol | year= 2017 | volume= 69 | issue= 1 | pages= 84-99 | pmid=27284942 | doi=10.23736/S0026-4784.16.03943-5 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27284942  }} </ref>
*Ovarian cancer the fifth most common cause of cancer-related mortality in women
+
*[[Ovarian cancer]] is the fifth most common cause of cancer-related [[mortality]] in women
*75% of women with ovarian cancer are diagnosed in an advanced stage
+
*75% of women with [[ovarian cancer]] are diagnosed in an advanced stage
*Ovarian cancer is the most lethal gynecological cancer<ref name="pmid28170086">{{cite journal| author=Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D et al.| title=Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. | journal=CA Cancer J Clin | year= 2017 | volume= 67 | issue= 2 | pages= 100-121 | pmid=28170086 | doi=10.3322/caac.21392 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28170086  }} </ref>
+
*[[Ovarian cancer]] is the most [[lethal]] [[gynecological]] [[cancer]]<ref name="pmid28170086">{{cite journal| author=Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D et al.| title=Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. | journal=CA Cancer J Clin | year= 2017 | volume= 67 | issue= 2 | pages= 100-121 | pmid=28170086 | doi=10.3322/caac.21392 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28170086  }} </ref>
*The reason of increased mortality and late detection of ovarian cancer in its advanced stage is because the screening systems that are being used have poor or limited sensitivity and specificity<ref name="pmid27284942">{{cite journal| author=Galea M, Gauci G, Calleja-Agius J, Schembri-Wismayer P| title=Peritoneal biomarkers in the early detection of ovarian cancer. | journal=Minerva Ginecol | year= 2017 | volume= 69 | issue= 1 | pages= 84-99 | pmid=27284942 | doi=10.23736/S0026-4784.16.03943-5 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27284942  }} </ref>.
+
*The reason of increased [[mortality]] and late detection of [[ovarian cancer]] in its advanced stage is because the [[screening]] systems that are being used have poor or limited [[sensitivity]] and [[specificity]]<ref name="pmid27284942">{{cite journal| author=Galea M, Gauci G, Calleja-Agius J, Schembri-Wismayer P| title=Peritoneal biomarkers in the early detection of ovarian cancer. | journal=Minerva Ginecol | year= 2017 | volume= 69 | issue= 1 | pages= 84-99 | pmid=27284942 | doi=10.23736/S0026-4784.16.03943-5 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27284942  }} </ref>.
*Biomarkers from peritoneal fluid can be used as a mean of ealy detection of ovarian cancer but this is stil an emerging proof.
+
*[[Biomarkers]] from [[peritoneal fluid]] can be used as a mean of ealy detection of [[ovarian cancer]] but this is stil an emerging proof.
*Examples of screening and diagnostic methods for ovarian cancer include:
+
*Examples of [[screening]] and [[diagnostic]] methods for [[ovarian cancer]] include:
**elvic examination
+
**[[Pelvic examination]]
**Cancer antigen 125 (CA 125) tumor marker
+
**[[Cancer antigen 125]] ([[CA 125]]) [[tumor marker]]
**Transvaginal ultrasound (TVU)
+
**[[Transvaginal ultrasound]] ([[TVU]])
 
**Multimarker panels and bioinformatic analysis of proteomic patterns<ref name="pmid28170086">{{cite journal| author=Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D et al.| title=Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. | journal=CA Cancer J Clin | year= 2017 | volume= 67 | issue= 2 | pages= 100-121 | pmid=28170086 | doi=10.3322/caac.21392 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28170086  }} </ref>
 
**Multimarker panels and bioinformatic analysis of proteomic patterns<ref name="pmid28170086">{{cite journal| author=Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D et al.| title=Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. | journal=CA Cancer J Clin | year= 2017 | volume= 67 | issue= 2 | pages= 100-121 | pmid=28170086 | doi=10.3322/caac.21392 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28170086  }} </ref>
 
+
*The UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)is evaluating a multimodal screening strategy (MMS) efficacy which consists of:
 +
**annual CA 125 screening, risk of ovarian cancer algorithm (ROCA), TVU <ref name="pmid28170086">{{cite journal| author=Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D et al.| title=Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. | journal=CA Cancer J Clin | year= 2017 | volume= 67 | issue= 2 | pages= 100-121 | pmid=28170086 | doi=10.3322/caac.21392 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28170086  }} </ref>
 +
*Patients with family history of ovarian cancer or breast cancer can have ovarian cancer hereditary syndrome as breast-ovarian cancer syndrome which is associated with
 +
**BRCA1 and BRCA2 gene mutations
 +
**Lynch II syndrome
 +
*Should undergo the following screening:
 +
**Annual rectovaginal pelvic examinations
 +
**CA 125
 +
**TVU untilcompleting childbearing or until age 35 years at least, where at this point prophylactic bilateral oophorectomy is recommended
 
== References ==
 
== References ==
 
{{reflist|2}}
 
{{reflist|2}}

Revision as of 18:34, 12 July 2019


Ovarian cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classifications

Pathophysiology

Causes of Ovarian cancer

Differentiating Ovarian cancer from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

History & Symptoms

Physical Examination

Staging

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Ovarian cancer screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Ovarian cancer screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Ovarian cancer screening

CDC on Ovarian cancer screening

Ovarian cancer screening in the news

Blogs on Ovarian cancer screening

Directions to Hospitals Treating Ovarian cancer

Risk calculators and risk factors for Ovarian cancer screening

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

References

  1. 1.0 1.1 Galea M, Gauci G, Calleja-Agius J, Schembri-Wismayer P (2017). "Peritoneal biomarkers in the early detection of ovarian cancer". Minerva Ginecol. 69 (1): 84–99. doi:10.23736/S0026-4784.16.03943-5. PMID 27284942.
  2. 2.0 2.1 2.2 Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D; et al. (2017). "Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening". CA Cancer J Clin. 67 (2): 100–121. doi:10.3322/caac.21392. PMID 28170086.

Linked-in.jpg